Loading...
Sign in to edit your profile (add interests, mentoring, photo, etc.)

    David Braff

    TitleEmeritus Professor
    SchoolUniversity of California, San Diego
    DepartmentPsychiatry
    Address9500 Gilman Drive #0804
    CA La Jolla 92093
    Phone619-543-5570
    vCardDownload vCard

      Collapse Overview 
      Collapse Overview

      Biography

      David Braff, M.D. is Distinguished Professor of Psychiatry, and Director of the Schizophrenia Program at the University of California, San Diego, School of Medicine. He is also Director of the NIH-funded Consortium on the Genetics of Schizophrenia (COGS). He trained at the University of Pennsylvania, Yale University, and the University of California, San Francisco.

      Research Interests

      David Braff, M.D. is Distinguished Professor of Psychiatry, and Director of the Schizophrenia Program at the Department of Psychiatry, University of California San Diego School of Medicine. He is also Director and Lead Scientist of the NIH-funded multi-site Consortium on the Genetics of Schizophrenia (COGS). He trained at the University of Pennsylvania, Yale University, and the University of California, San Francisco.

      David Braff’s research interests have received long-term NIMH and NARSAD Distinguished Investigator funding and a special NIMH MERIT Award to extend his research as well as funding from the Veterans Administration. His interests center around 1) the identification of neurocognitive and neurophysiological biomarker deficits in psychiatric disorders (with an emphasis on schizophrenia); 2) understanding the neural circuit/substrate dysfunctions of schizophrenia patients using human and cross-species translational animal model studies; 3) using neurocognitive, imaging, information processing, and attentional dysregulation as endophenotypes in family/genetic studies; 4) utilizing translational and genetic research tools to identify the neural circuit basis and the genetic architecture of neuropsychiatric disorders such as schizophrenia; and 5) utilizing genetically and behaviorally determined, strong inference-based targets for developing efficacious antipsychotic medications and psychosocial therapies that can improve the functional outcome and quality of life of schizophrenia patients and reduce the devastating disease burden placed on them and their families by this “no fault” clinical brain disorder.

      David Braff has published over 250 articles and 300 reviews, book chapters and abstracts. He has received special recognition from the Institute for Scientific Information (ISI) as being in the top half of 1% of most highly cited neuropsychiatric researchers. In addition, he has been the Attending Physician for over 10,000 patients with schizophrenia and other serious mental disorders, and has trained many researchers and clinicians. Dr. Braff has served as Councilor, Executive Secretary and President of the Society of Biological Psychiatry (SOBP), and as a Councilor and President of the American College of Neuropsychopharmacology (ACNP), 2 world leading neuropsychiatric research societies. He has consulted to the Diagnostic and Statistical Manual (DSM IV and V) Committee of the APA, and Expert Treatment Committee of the American Psychiatric Association (APA). He is the Co-Chair of the Executive Committee and Director of the Clinical Neurosciences and Genomic Unit at the Veterans Administration VISN 22 Mental Illness, Research and Clinical Center (MIRECC) program in the Southwest United States which investigates psychosis and its treatment. He has also been a key figure in advancing the Mission of the International Congress on Schizophrenia Research (ICOSR) and liaisoned USA-Russia and USA-China cultural and grant cooperative projects. He served for 15 years as President of the campus-wide UCSD Faculty Association.

      David Braff has received numerous Grants, Awards, and Prizes. A Fellow of the American Psychiatric Association (APA), Dr. Braff received the Kempf Research Prize and Marmor Award for excellence in biopsychosocial research from the APA, as well as the Gold Medal for lifetime research accomplishments from the SOBP, and the Warren Award for schizophrenia research from the ICOSR. He received the George Thompson Award from the SOBP for service to the field, the Dean Award for Schizophrenia Research Excellence from the American College of Psychiatrists (ACP) as well as Gold Medal for psychiatric research from Society of Biological Psychiatry with other awards. He has been selected by his peers as one of the “Best Doctors” in the United States and in San Diego. He serves on many national and international committees and societies, such as the Executive Committee of the MATRICS Project of the NIMH, which identified novel cognitive targets for antipsychotic medications, and other NIMH advisory committees that focus on issues such as the design and conduct of large clinical treatment trials. Dr. Braff is on the Editorial Boards of the Archives of General Psychiatry and five other journals and reviews manuscripts for over 20 Top Journals. He has lectured nationally and internationally on many topics in neuropsychiatric science and practice, and is recognized as a leader of the international neuropsychiatric community.


      Collapse Research 
      Collapse Research Activities and Funding
      2/5-Gentics of Transcriptional Endophenotypes for Schizophrenia
      NIH/NIMH R01MH093533Apr 15, 2012 - Mar 31, 2015
      Role: Principal Investigator
      5/5:Family-Based Genome-Wide Methylation Scan in Neurocognition and Schizophrenia
      NIH/NIMH RC2MH089984Sep 30, 2009 - Aug 31, 2011
      Role: Principal Investigator
      4/4-A Genomic Approach to Schizophrenia
      NIH/NIMH R01MH084071Apr 16, 2009 - Jan 31, 2014
      Role: Principal Investigator
      5/5: A Genome-wide Methylation Scan for Epigenetic Contributions to Schizophrenia
      NIH/NIMH U01MH085265Sep 30, 2008 - May 31, 2014
      Role: Principal Investigator
      1/6-The Genetics of Endophenotypes and Schizophrenia
      NIH/NIMH R01MH065571Apr 4, 2003 - Jan 31, 2014
      Role: Principal Investigator
      Gating and Inhibiting in Schizophrenia
      NIH/NIMH R01MH042228Jan 1, 1987 - Apr 30, 2016
      Role: Principal Investigator
      SENSORY GATING AND HABITUATION IN SCHIZOPHRENIA
      NIH/NIMH R37MH042228Jan 1, 1987 - Apr 16, 2003
      Role: Principal Investigator
      General Clinical Research Center
      NIH/NCRR M01RR000827Mar 1, 1974 - Nov 30, 2010
      Role: Co-Investigator

      Collapse Bibliographic 
      Collapse Publications
      Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help.
      List All   |   Timeline
      1. Swerdlow NR, Light GA, Thomas ML, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff D. Deficient prepulse inhibition in schizophrenia in a multi-site cohort: Internal replication and extension. Schizophr Res. 2017 May 23. PMID: 28549722.
        View in: PubMed
      2. Perez VB, Tarasenko M, Miyakoshi M, Pianka ST, Makeig SD, Braff D, Swerdlow NR, Light GA. Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia. Neuropsychopharmacology. 2017 Jan 31. PMID: 28139679.
        View in: PubMed
      3. Thomas ML, Green MF, Hellemann G, Sugar CA, Tarasenko M, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Shiluk AL, Siever LJ, Silverman JM, Sprock J, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff D, Light GA. Modeling Deficits From Early Auditory Information Processing to Psychosocial Functioning in Schizophrenia. JAMA Psychiatry. 2016 Dec 07. PMID: 27926742.
        View in: PubMed
      4. Swerdlow NR, Braff D, Geyer MA. Sensorimotor gating of the startle reflex: what we said 25 years ago, what has happened since then, and what comes next. J Psychopharmacol. 2016 Nov; 30(11):1072-1081. PMID: 27539931.
        View in: PubMed
      5. Krystal JH, Abi-Dargham A, Akbarian S, Arnsten AF, Barch DM, Bearden CE, Braff D, Brown ES, Bullmore ET, Carlezon WA, Carter CS, Cook EH, Daskalakis ZJ, DiLeone RJ, Duman RS, Grace AA, Hariri AR, Harrison PJ, Hiroi N, Kenny PJ, Kleinman JE, Krystal AD, Lewis DA, Lipska BK, Marder SR, Mason GF, Mathalon DH, McClung CA, McDougle CJ, McIntosh AM, McMahon FJ, Mirnics K, Monteggia LM, Narendran R, Nestler EJ, Neumeister A, O'Donovan MC, Öngür D, Pariante CM, Paulus MP, Pearlson G, Phillips ML, Pine DS, Pizzagalli DA, Pletnikov MV, Ragland JD, Rapoport JL, Ressler KJ, Russo SJ, Sanacora G, Sawa A, Schatzberg AF, Shaham Y, Shamay-Tsoory SG, Sklar P, State MW, Stein MB, Strakowski SM, Taylor SF, Turecki G, Turetsky BI, Weissman MM, Zachariou V, Zarate CA, Zubieta JK. Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biol Psychiatry. 2016 Jul 15; 80(2):84-6. PMID: 27346079.
        View in: PubMed
      6. Montano C, Taub MA, Jaffe A, Briem E, Feinberg JI, Trygvadottir R, Idrizi A, Runarsson A, Berndsen B, Gur RC, Moore TM, Perry RT, Fugman D, Sabunciyan S, Yolken RH, Hyde TM, Kleinman JE, Sobell JL, Pato CN, Pato MT, Go RC, Nimgaonkar V, Weinberger DR, Braff D, Gur RE, Fallin MD, Feinberg AP. Association of DNA Methylation Differences With Schizophrenia in an Epigenome-Wide Association Study. JAMA Psychiatry. 2016 May 1; 73(5):506-14. PMID: 27074206.
        View in: PubMed
      7. Millard SP, Shofer J, Braff D, Calkins M, Cadenhead K, Freedman R, Green MF, Greenwood TA, Gur R, Gur R, Lazzeroni LC, Light GA, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone WS, Sprock J, Sugar CA, Swerdlow NR, Tsuang M, Turetsky B, Radant A, Tsuang DW. Prioritizing schizophrenia endophenotypes for future genetic studies: An example using data from the COGS-1 family study. Schizophr Res. 2016 Jul; 174(1-3):1-9. PMID: 27132484.
        View in: PubMed
      8. Tarasenko M, Perez VB, Pianka ST, Vinogradov S, Braff D, Swerdlow NR, Light GA. Measuring the capacity for auditory system plasticity: An examination of performance gains during initial exposure to auditory-targeted cognitive training in schizophrenia. Schizophr Res. 2016 Apr; 172(1-3):123-30. PMID: 26851143.
        View in: PubMed
      9. Greenwood TA, Lazzeroni LC, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff D. Genetic assessment of additional endophenotypes from the Consortium on the Genetics of Schizophrenia Family Study. Schizophr Res. 2016 Jan; 170(1):30-40. PMID: 26597662.
        View in: PubMed
      10. Greenwood TA, Light GA, Swerdlow NR, Calkins ME, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff D. Gating Deficit Heritability and Correlation With Increased Clinical Severity in Schizophrenia Patients With Positive Family History. Am J Psychiatry. 2016 Apr 1; 173(4):385-91. PMID: 26441157.
        View in: PubMed
      11. Gur RC, Braff D, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Gur RE. Neurocognitive performance in family-based and case-control studies of schizophrenia. Schizophr Res. 2015 Apr; 163(1-3):17-23. PMID: 25432636.
        View in: PubMed
      12. Braff D. The importance of endophenotypes in schizophrenia research. Schizophr Res. 2015 Apr; 163(1-3):1-8. PMID: 25795083.
        View in: PubMed
      13. Nuechterlein KH, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff D. Attention/vigilance in schizophrenia: Performance results from a large multi-site study of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):38-46. PMID: 25749017.
        View in: PubMed
      14. Seidman LJ, Hellemann G, Nuechterlein KH, Greenwood TA, Braff D, Cadenhead KS, Calkins ME, Freedman R, Gur RE, Gur RC, Lazzeroni LC, Light GA, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Factor structure and heritability of endophenotypes in schizophrenia: Findings from the Consortium on the Genetics of Schizophrenia (COGS-1). Schizophr Res. 2015 Apr; 163(1-3):73-9. PMID: 25682549.
        View in: PubMed
      15. Radant AD, Millard SP, Braff D, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Meichle SP, Nuechterlein KH, Olincy A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Sugar CA, Tsuang MT, Turetsky BI, Tsuang DW. Robust differences in antisaccade performance exist between COGS schizophrenia cases and controls regardless of recruitment strategies. Schizophr Res. 2015 Apr; 163(1-3):47-52. PMID: 25553977.
        View in: PubMed
      16. Stone WS, Mesholam-Gately RI, Braff D, Calkins ME, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Olincy A, Radant AD, Siever LJ, Silverman JM, Sprock J, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Seidman LJ. California Verbal Learning Test-II performance in schizophrenia as a function of ascertainment strategy: Comparing the first and second phases of the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2015 Apr; 163(1-3):32-7. PMID: 25497440.
        View in: PubMed
      17. Braff D. Genomic substrates of neurophysiological endophenotypes: Where we've been and where we're going. Psychophysiology. 2014 Dec; 51(12):1323-4. PMID: 25387712.
        View in: PubMed
      18. Braff D. Enoch callaway. Neuropsychopharmacology. 2014 Dec; 39(13):3125. PMID: 25381704.
        View in: PubMed
      19. van Tricht MJ, Bour LJ, Koelman JH, Derks EM, Braff D, de Wilde OM, Boerée T, Linszen DH, de Haan L, Nieman DH. Qualitative and quantitative aspects of information processing in first psychosis: Latent class analyses in patients, at-risk subjects, and controls. Psychophysiology. 2015 Apr; 52(4):585-93. PMID: 25376718.
        View in: PubMed
      20. Swerdlow NR, Gur RE, Braff D. Consortium on the Genetics of Schizophrenia (COGS) assessment of endophenotypes for schizophrenia: an introduction to this Special Issue of Schizophrenia Research. Schizophr Res. 2015 Apr; 163(1-3):9-16. PMID: 25454799.
        View in: PubMed
      21. Light GA, Swerdlow NR, Thomas ML, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Pela M, Radant AD, Seidman LJ, Sharp RF, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Braff D, Turetsky BI. Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: Characterization of demographic, clinical, cognitive, and functional correlates in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):63-72. PMID: 25449710.
        View in: PubMed
      22. Tarasenko MA, Swerdlow NR, Makeig S, Braff D, Light GA. The auditory brain-stem response to complex sounds: a potential biomarker for guiding treatment of psychosis. Front Psychiatry. 2014; 5:142. PMID: 25352811.
        View in: PubMed
      23. Turetsky BI, Dress EM, Braff D, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Light G. The utility of P300 as a schizophrenia endophenotype and predictive biomarker: Clinical and socio-demographic modulators in COGS-2. Schizophr Res. 2015 Apr; 163(1-3):53-62. PMID: 25306203.
        View in: PubMed
      24. Rissling AJ, Miyakoshi M, Sugar CA, Braff D, Makeig S, Light GA. Cortical substrates and functional correlates of auditory deviance processing deficits in schizophrenia. Neuroimage Clin. 2014; 6:424-37. PMID: 25379456.
        View in: PubMed
      25. Lee J, Green MF, Calkins ME, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Light GA, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff D. Verbal working memory in schizophrenia from the Consortium on the Genetics of Schizophrenia (COGS) Study: The moderating role of smoking status and antipsychotic medications. Schizophr Res. 2015 Apr; 163(1-3):24-31. PMID: 25248939.
        View in: PubMed
      26. Light G, Greenwood TA, Swerdlow NR, Calkins ME, Freedman R, Green MF, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Sprock J, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff D. Comparison of the Heritability of Schizophrenia and Endophenotypes in the COGS-1 Family Study. Schizophr Bull. 2014 Nov; 40(6):1404-11. PMID: 24903414.
        View in: PubMed
      27. Schmeidler J, Lazzeroni LC, Swerdlow NR, Ferreira RP, Braff D, Calkins ME, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Olincy A, Nuechterlein KH, Radant AD, Seidman LJ, Siever LJ, Stone WS, Sprock J, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Silverman JM. Paternal age of schizophrenia probands and endophenotypic differences from unaffected siblings. Psychiatry Res. 2014 Sep 30; 219(1):67-71. PMID: 24913833.
        View in: PubMed
      28. Tsuang D, Esterberg M, Braff D, Calkins M, Cadenhead K, Dobie D, Freedman R, Green MF, Greenwood T, Gur R, Gur R, Horan W, Lazzeroni LC, Light GA, Millard SP, Olincy A, Nuechterlein K, Seidman L, Siever L, Silverman J, Stone W, Sprock J, Sugar C, Swerdlow N, Tsuang M, Turetsky B, Radant A. Is There an Association between Advanced Paternal Age and Endophenotype Deficit Levels in Schizophrenia? PLoS One. 2014; 9(2):e88379. PMID: 24523888.
        View in: PubMed
      29. Swerdlow NR, Light GA, Sprock J, Calkins ME, Green MF, Greenwood TA, Gur RE, Gur RC, Lazzeroni LC, Nuechterlein KH, Radant AD, Ray A, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Braff D. Deficient prepulse inhibition in schizophrenia detected by the multi-site COGS. Schizophr Res. 2014 Feb; 152(2-3):503-12. PMID: 24405980.
        View in: PubMed
      30. Perez VB, Swerdlow NR, Braff D, Näätänen R, Light GA. Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses. Biomark Med. 2014 Jan; 8(1):9-14. PMID: 24325220.
        View in: PubMed
      31. Braff L, Braff D. The neuropsychiatric translational revolution: still very early and still very challenging. JAMA Psychiatry. 2013 Aug; 70(8):777-9. PMID: 23739986.
        View in: PubMed
      32. Gulsuner S, Walsh T, Watts AC, Lee MK, Thornton AM, Casadei S, Rippey C, Shahin H. Spatial and temporal mapping of de novo mutations in schizophrenia to a fetal prefrontal cortical network. Cell. 2013 Aug 1; 154(3):518-29. PMID: 23911319.
        View in: PubMed
      33. Braff D, Ryan J, Rissling AJ, Carpenter WT. Lack of use in the literature from the last 20 years supports dropping traditional schizophrenia subtypes from DSM-5 and ICD-11. Schizophr Bull. 2013 Jul; 39(4):751-3. PMID: 23674819.
        View in: PubMed
      34. Greenwood TA, Swerdlow NR, Gur RE, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RC, Lazzeroni LC, Nuechterlein KH, Olincy A, Radant AD, Ray A, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar CA, Tsuang DW, Tsuang MT, Turetsky BI, Light GA, Braff D. Genome-wide linkage analyses of 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2013 May 1; 170(5):521-32. PMID: 23511790.
        View in: PubMed
      35. Rissling AJ, Park SH, Young JW, Rissling MB, Sugar CA, Sprock J, Mathias DJ, Pela M, Sharp RF, Braff D, Light GA. Demand and modality of directed attention modulate "pre-attentive" sensory processes in schizophrenia patients and nonpsychiatric controls. Schizophr Res. 2013 May; 146(1-3):326-35. PMID: 23490760.
        View in: PubMed
      36. Calkins ME, Ray A, Gur RC, Freedman R, Green MF, Greenwood TA, Light GA, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Sugar C, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff D, Lazzeroni LC, Gur RE. Sex differences in familiality effects on neurocognitive performance in schizophrenia. Biol Psychiatry. 2013 May 15; 73(10):976-84. PMID: 23395246.
        View in: PubMed
      37. Takahashi H, Rissling AJ, Pascual-Marqui R, Kirihara K, Pela M, Sprock J, Braff D, Light GA. Neural substrates of normal and impaired preattentive sensory discrimination in large cohorts of nonpsychiatric subjects and schizophrenia patients as indexed by MMN and P3a change detection responses. Neuroimage. 2013 Feb 1; 66:594-603. PMID: 23085112.
        View in: PubMed
      38. Light GA, Swerdlow NR, Rissling AJ, Radant A, Sugar CA, Sprock J, Pela M, Geyer MA, Braff D. Characterization of neurophysiologic and neurocognitive biomarkers for use in genomic and clinical outcome studies of schizophrenia. PLoS One. 2012; 7(7):e39434. PMID: 22802938.
        View in: PubMed
      39. Rissling AJ, Braff D, Swerdlow NR, Hellemann G, Rassovsky Y, Sprock J, Pela M, Light GA. Disentangling early sensory information processing deficits in schizophrenia. Clin Neurophysiol. 2012 Oct; 123(10):1942-9. PMID: 22608970.
        View in: PubMed
      40. Kirihara K, Rissling AJ, Swerdlow NR, Braff D, Light GA. Hierarchical organization of gamma and theta oscillatory dynamics in schizophrenia. Biol Psychiatry. 2012 May 15; 71(10):873-80. PMID: 22361076.
        View in: PubMed
      41. Greenwood TA, Light GA, Swerdlow NR, Radant AD, Braff D. Association analysis of 94 candidate genes and schizophrenia-related endophenotypes. PLoS One. 2012; 7(1):e29630. PMID: 22253750.
        View in: PubMed
      42. Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Gur RE, Gur RC, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff D. Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Am J Psychiatry. 2011 Sep; 168(9):930-46. PMID: 21498463.
        View in: PubMed
      43. Braff D. Gating in schizophrenia: from genes to cognition (to real world function?). Biol Psychiatry. 2011 Mar 1; 69(5):395-6. PMID: 21316513.
        View in: PubMed
      44. Stone WS, Giuliano AJ, Tsuang MT, Braff D, Cadenhead KS, Calkins ME, Dobie DJ, Faraone SV, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Roe AH, Schork NJ, Siever LJ, Silverman JM, Swerdlow NR, Thomas AR, Tsuang DW, Turetsky BI, Seidman LJ. Group and site differences on the California Verbal Learning Test in persons with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia (COGS). Schizophr Res. 2011 May; 128(1-3):102-10. PMID: 21288694.
        View in: PubMed
      45. Rissling AJ, Makeig S, Braff D, Light GA. Neurophysiologic markers of abnormal brain activity in schizophrenia. Curr Psychiatry Rep. 2010 Dec; 12(6):572-8. PMID: 20857348.
        View in: PubMed
      46. Williams LE, Ramachandran VS, Hubbard EM, Braff D, Light GA. Superior size-weight illusion performance in patients with schizophrenia: evidence for deficits in forward models. Schizophr Res. 2010 Aug; 121(1-3):101-6. PMID: 19931421.
        View in: PubMed
      47. Light GA, Williams LE, Minow F, Sprock J, Rissling A, Sharp R, Swerdlow NR, Braff D. Electroencephalography (EEG) and event-related potentials (ERPs) with human participants. Curr Protoc Neurosci. 2010 Jul; Chapter 6:Unit 6.25.1-24. PMID: 20578033.
        View in: PubMed
      48. Williams LE, Light GA, Braff D, Ramachandran VS. Reduced multisensory integration in patients with schizophrenia on a target detection task. Neuropsychologia. 2010 Aug; 48(10):3128-36. PMID: 20600181.
        View in: PubMed
      49. Olincy A, Braff D, Adler LE, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Wagner BD, Freedman R. Inhibition of the P50 cerebral evoked response to repeated auditory stimuli: results from the Consortium on Genetics of Schizophrenia. Schizophr Res. 2010 Jun; 119(1-3):175-82. PMID: 20382002.
        View in: PubMed
      50. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff D, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Meichle SP, Millard SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Antisaccade performance in schizophrenia patients, their first-degree biological relatives, and community comparison subjects: data from the COGS study. Psychophysiology. 2010 Sep; 47(5):846-56. PMID: 20374545.
        View in: PubMed
      51. Braff D. Prepulse inhibition of the startle reflex: a window on the brain in schizophrenia. Curr Top Behav Neurosci. 2010; 4:349-71. PMID: 21312406.
        View in: PubMed
      52. Kiang M, Braff D, Sprock J, Light GA. The relationship between preattentive sensory processing deficits and age in schizophrenia patients. Clin Neurophysiol. 2009 Nov; 120(11):1949-57. PMID: 19786365.
        View in: PubMed
      53. Nasrallah HA, Keshavan MS, Benes FM, Braff D, Green AI, Gur RE, Kane JM, Perkins DO, Weiden PJ, Weinberger DR, Correll CU. Proceedings and data from The Schizophrenia Summit: a critical appraisal to improve the management of Schizophrenia. J Clin Psychiatry. 2009; 70 Suppl 1:4-46. PMID: 19292973.
        View in: PubMed
      54. Turetsky BI, Greenwood TA, Olincy A, Radant AD, Braff D, Cadenhead KS, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Calkins ME. Abnormal auditory N100 amplitude: a heritable endophenotype in first-degree relatives of schizophrenia probands. Biol Psychiatry. 2008 Dec 15; 64(12):1051-9. PMID: 18701089.
        View in: PubMed
      55. Braff D, Freedman R. Clinically responsible genetic testing in neuropsychiatric patients: a bridge too far and too soon. Am J Psychiatry. 2008 Aug; 165(8):952-5. PMID: 18676598.
        View in: PubMed
      56. Swerdlow NR, Weber M, Qu Y, Light GA, Braff D. Realistic expectations of prepulse inhibition in translational models for schizophrenia research. Psychopharmacology (Berl). 2008 Aug; 199(3):331-88. PMID: 18568339.
        View in: PubMed
      57. Krystal JH, Carter CS, Geschwind D, Manji HK, March JS, Nestler EJ, Zubieta JK, Charney DS, Goldman D, Gur RE, Lieberman JA, Roy-Byrne P, Rubinow DR, Anderson SA, Barondes S, Berman KF, Blair J, Braff D, Brown ES, Calabrese JR, Carlezon WA, Cook EH, Davidson RJ, Davis M, Desimone R, Drevets WC, Duman RS, Essock SM, Faraone SV, Freedman R, Friston KJ, Gelernter J, Geller B, Gill M, Gould E, Grace AA, Grillon C, Gueorguieva R, Hariri AR, Innis RB, Jones EG, Kleinman JE, Koob GF, Krystal AD, Leibenluft E, Levinson DF, Levitt PR, Lewis DA, Liberzon I, Lipska BK, Marder SR, Markou A, Mason GF, McDougle CJ, McEwen BS, McMahon FJ, Meaney MJ, Meltzer HY, Merikangas KR, Meyer-Lindenberg A, Mirnics K, Monteggia LM, Neumeister A, O'Brien CP, Owen MJ, Pine DS, Rapoport JL, Rauch SL, Robbins TW, Rosenbaum JF, Rosenberg DR, Ross CA, Rush AJ, Sackeim HA, Sanacora G, Schatzberg AF, Shaham Y, Siever LJ, Sunderland T, Tecott LH, Thase ME, Todd RD, Weissman MM, Yehuda R, Yoshikawa T, Young EA, McCandless R. It is time to take a stand for medical research and against terrorism targeting medical scientists. Biol Psychiatry. 2008 Apr 15; 63(8):725-7. PMID: 18371494.
        View in: PubMed
      58. Horan WP, Braff D, Nuechterlein KH, Sugar CA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Green MF. Verbal working memory impairments in individuals with schizophrenia and their first-degree relatives: findings from the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2008 Aug; 103(1-3):218-28. PMID: 18406578.
        View in: PubMed
      59. Braff D, Greenwood TA, Swerdlow NR, Light GA, Schork NJ. Advances in endophenotyping schizophrenia. World Psychiatry. 2008 Feb; 7(1):11-8. PMID: 18458787.
        View in: PubMed
      60. Kiang M, Kutas M, Light GA, Braff D. An event-related brain potential study of direct and indirect semantic priming in schizophrenia. Am J Psychiatry. 2008 Jan; 165(1):74-81. PMID: 18056222.
        View in: PubMed
      61. Greenwood TA, Braff D, Light GA, Cadenhead KS, Calkins ME, Dobie DJ, Freedman R, Green MF, Gur RE, Gur RC, Mintz J, Nuechterlein KH, Olincy A, Radant AD, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Schork NJ. Initial heritability analyses of endophenotypic measures for schizophrenia: the consortium on the genetics of schizophrenia. Arch Gen Psychiatry. 2007 Nov; 64(11):1242-50. PMID: 17984393.
        View in: PubMed
      62. Sergi MJ, Green MF, Widmark C, Reist C, Erhart S, Braff D, Kee KS, Marder SR, Mintz J. Social cognition [corrected] and neurocognition: effects of risperidone, olanzapine, and haloperidol. Am J Psychiatry. 2007 Oct; 164(10):1585-92. PMID: 17898351.
        View in: PubMed
      63. Light GA, Swerdlow NR, Braff D. Preattentive sensory processing as indexed by the MMN and P3a brain responses is associated with cognitive and psychosocial functioning in healthy adults. J Cogn Neurosci. 2007 Oct; 19(10):1624-32. PMID: 18271737.
        View in: PubMed
      64. Wynn JK, Green MF, Sprock J, Light GA, Widmark C, Reist C, Erhart S, Marder SR, Mintz J, Braff D. Effects of olanzapine, risperidone and haloperidol on prepulse inhibition in schizophrenia patients: a double-blind, randomized controlled trial. Schizophr Res. 2007 Sep; 95(1-3):134-42. PMID: 17662577.
        View in: PubMed
      65. Kiang M, Light GA, Prugh J, Coulson S, Braff D, Kutas M. Cognitive, neurophysiological, and functional correlates of proverb interpretation abnormalities in schizophrenia. J Int Neuropsychol Soc. 2007 Jul; 13(4):653-63. PMID: 17521483.
        View in: PubMed
      66. Braff D, Schork NJ, Gottesman II. Endophenotyping schizophrenia. Am J Psychiatry. 2007 May; 164(5):705-7. PMID: 17475726.
        View in: PubMed
      67. Kiang M, Kutas M, Light GA, Braff D. Electrophysiological insights into conceptual disorganization in schizophrenia. Schizophr Res. 2007 May; 92(1-3):225-36. PMID: 17383161.
        View in: PubMed
      68. Swerdlow NR, Sprock J, Light GA, Cadenhead K, Calkins ME, Dobie DJ, Freedman R, Green MF, Greenwood TA, Gur RE, Mintz J, Olincy A, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Tsuang DW, Tsuang MT, Turetsky BI, Braff D. Multi-site studies of acoustic startle and prepulse inhibition in humans: initial experience and methodological considerations based on studies by the Consortium on the Genetics of Schizophrenia. Schizophr Res. 2007 May; 92(1-3):237-51. PMID: 17346930.
        View in: PubMed
      69. Braff D, Light GA, Swerdlow NR. Prepulse inhibition and P50 suppression are both deficient but not correlated in schizophrenia patients. Biol Psychiatry. 2007 May 15; 61(10):1204-7. PMID: 17161386.
        View in: PubMed
      70. Sergi MJ, Rassovsky Y, Widmark C, Reist C, Erhart S, Braff D, Marder SR, Green MF. Social cognition in schizophrenia: relationships with neurocognition and negative symptoms. Schizophr Res. 2007 Feb; 90(1-3):316-24. PMID: 17141477.
        View in: PubMed
      71. Swerdlow NR, Light GA, Cadenhead KS, Sprock J, Hsieh MH, Braff D. Startle gating deficits in a large cohort of patients with schizophrenia: relationship to medications, symptoms, neurocognition, and level of function. Arch Gen Psychiatry. 2006 Dec; 63(12):1325-35. PMID: 17146007.
        View in: PubMed
      72. Braff D, Freedman R, Schork NJ, Gottesman II. Deconstructing schizophrenia: an overview of the use of endophenotypes in order to understand a complex disorder. Schizophr Bull. 2007 Jan; 33(1):21-32. PMID: 17088422.
        View in: PubMed
      73. Calkins ME, Dobie DJ, Cadenhead KS, Olincy A, Freedman R, Green MF, Greenwood TA, Gur RE, Gur RC, Light GA, Mintz J, Nuechterlein KH, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Braff D. The Consortium on the Genetics of Endophenotypes in Schizophrenia: model recruitment, assessment, and endophenotyping methods for a multisite collaboration. Schizophr Bull. 2007 Jan; 33(1):33-48. PMID: 17035358.
        View in: PubMed
      74. Schork NJ, Greenwood TA, Braff D. Statistical genetics concepts and approaches in schizophrenia and related neuropsychiatric research. Schizophr Bull. 2007 Jan; 33(1):95-104. PMID: 17035359.
        View in: PubMed
      75. Radant AD, Dobie DJ, Calkins ME, Olincy A, Braff D, Cadenhead KS, Freedman R, Green MF, Greenwood TA, Gur RE, Light GA, Meichle SP, Mintz J, Nuechterlein KH, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang MT, Turetsky BI, Tsuang DW. Successful multi-site measurement of antisaccade performance deficits in schizophrenia. Schizophr Res. 2007 Jan; 89(1-3):320-9. PMID: 17023145.
        View in: PubMed
      76. McDowell JE, Brown GG, Lazar N, Camchong J, Sharp R, Krebs-Thomson K, Eyler LT, Braff D, Geyer MA. The neural correlates of habituation of response to startling tactile stimuli presented in a functional magnetic resonance imaging environment. Psychiatry Res. 2006 Nov 22; 148(1):1-10. PMID: 17000088.
        View in: PubMed
      77. Light GA, Hsu JL, Hsieh MH, Meyer-Gomes K, Sprock J, Swerdlow NR, Braff D. Gamma band oscillations reveal neural network cortical coherence dysfunction in schizophrenia patients. Biol Psychiatry. 2006 Dec 1; 60(11):1231-40. PMID: 16893524.
        View in: PubMed
      78. Swerdlow NR, Geyer MA, Shoemaker JM, Light GA, Braff D, Stevens KE, Sharp R, Breier M, Neary A, Auerbach PP. Convergence and divergence in the neurochemical regulation of prepulse inhibition of startle and N40 suppression in rats. Neuropsychopharmacology. 2006 Mar; 31(3):506-15. PMID: 16123772.
        View in: PubMed
      79. Swerdlow NR, Sprock J, Braff D. Prepulse-elicited motor reactions do not differ between schizophrenia patients and control subjects. Behav Neurosci. 2006 Feb; 120(1):224-7. PMID: 16492135.
        View in: PubMed
      80. Hsieh MH, Swerdlow NR, Braff D. Effects of background and prepulse characteristics on prepulse inhibition and facilitation: implications for neuropsychiatric research. Biol Psychiatry. 2006 Mar 15; 59(6):555-9. PMID: 16169529.
        View in: PubMed
      81. Light GA, Braff D. Stability of mismatch negativity deficits and their relationship to functional impairments in chronic schizophrenia. Am J Psychiatry. 2005 Sep; 162(9):1741-3. PMID: 16135637.
        View in: PubMed
      82. Cadenhead KS, Light GA, Shafer KM, Braff D. P50 suppression in individuals at risk for schizophrenia: the convergence of clinical, familial, and vulnerability marker risk assessment. Biol Psychiatry. 2005 Jun 15; 57(12):1504-9. PMID: 15953486.
        View in: PubMed
      83. Meincke U, Light GA, Geyer MA, Braff D. On the waveform of the acoustic startle blink in the paradigm of prepulse inhibition - methodological and physiological aspects. Neuropsychobiology. 2005; 52(1):24-7. PMID: 15942260.
        View in: PubMed
      84. Swerdlow NR, Stephany NL, Talledo J, Light G, Braff D, Baeyens D, Auerbach PP. Prepulse inhibition of perceived stimulus intensity: paradigm assessment. Biol Psychol. 2005 May; 69(2):133-47. PMID: 15804542.
        View in: PubMed
      85. Braff D, Light GA, Ellwanger J, Sprock J, Swerdlow NR. Female schizophrenia patients have prepulse inhibition deficits. Biol Psychiatry. 2005 Apr 1; 57(7):817-20. PMID: 15820241.
        View in: PubMed
      86. Swerdlow NR, Talledo JA, Braff D. Startle modulation in Caucasian-Americans and Asian-Americans: a prelude to genetic/endophenotypic studies across the 'Pacific Rim'. Psychiatr Genet. 2005 Mar; 15(1):61-5. PMID: 15722959.
        View in: PubMed
      87. Light GA, Braff D. Mismatch negativity deficits are associated with poor functioning in schizophrenia patients. Arch Gen Psychiatry. 2005 Feb; 62(2):127-36. PMID: 15699289.
        View in: PubMed
      88. Braff D, Light GA. The use of neurophysiological endophenotypes to understand the genetic basis of schizophrenia. Dialogues Clin Neurosci. 2005; 7(2):125-35. PMID: 16262208.
        View in: PubMed
      89. Braff D, Light GA. Preattentional and attentional cognitive deficits as targets for treating schizophrenia. Psychopharmacology (Berl). 2004 Jun; 174(1):75-85. PMID: 15118804.
        View in: PubMed
      90. Meincke U, Light GA, Geyer MA, Braff D, Gouzoulis-Mayfrank E. Sensitization and habituation of the acoustic startle reflex in patients with schizophrenia. Psychiatry Res. 2004 Apr 15; 126(1):51-61. PMID: 15081627.
        View in: PubMed
      91. Lohr JB, Braff D. The value of referring to recently introduced antipsychotics as "second generation". Am J Psychiatry. 2003 Aug; 160(8):1371-2. PMID: 12900294.
        View in: PubMed
      92. Green MF, Mintz J, Salveson D, Nuechterlein KH, Breitmeyer B, Light GA, Braff D. Visual masking as a probe for abnormal gamma range activity in schizophrenia. Biol Psychiatry. 2003 Jun 15; 53(12):1113-9. PMID: 12814862.
        View in: PubMed
      93. Ellwanger J, Geyer MA, Braff D. The relationship of age to prepulse inhibition and habituation of the acoustic startle response. Biol Psychol. 2003 Mar; 62(3):175-95. PMID: 12633977.
        View in: PubMed
      94. Perry W, Minassian A, Cadenhead K, Sprock J, Braff D. The use of the Ego Impairment Index across the schizophrenia spectrum. J Pers Assess. 2003 Feb; 80(1):50-7. PMID: 12584067.
        View in: PubMed
      95. Paulus MP, Braff D. Chaos and schizophrenia: does the method fit the madness? Biol Psychiatry. 2003 Jan 1; 53(1):3-11. PMID: 12513940.
        View in: PubMed
      96. Paulus MP, Frank L, Brown GG, Braff D. Schizophrenia subjects show intact success-related neural activation but impaired uncertainty processing during decision-making. Neuropsychopharmacology. 2003 Apr; 28(4):795-806. PMID: 12655327.
        View in: PubMed
      97. Perry W, Feifel D, Minassian A, Bhattacharjie I, Braff D. Information processing deficits in acutely psychotic schizophrenia patients medicated and unmedicated at the time of admission. Am J Psychiatry. 2002 Aug; 159(8):1375-81. PMID: 12153831.
        View in: PubMed
      98. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, McDowell J, Braff D. Parietal dysfunction is associated with increased outcome-related decision-making in schizophrenia patients. Biol Psychiatry. 2002 Jun 15; 51(12):995-1004. PMID: 12062884.
        View in: PubMed
      99. Cadenhead KS, Light GA, Geyer MA, McDowell JE, Braff D. Neurobiological measures of schizotypal personality disorder: defining an inhibitory endophenotype? Am J Psychiatry. 2002 May; 159(5):869-71. PMID: 11986147.
        View in: PubMed
      100. Cadenhead KS, Braff D. Endophenotyping schizotypy: a prelude to genetic studies within the schizophrenia spectrum. Schizophr Res. 2002 Mar 1; 54(1-2):47-57. PMID: 11853978.
        View in: PubMed
      101. McDowell JE, Brown GG, Paulus M, Martinez A, Stewart SE, Dubowitz DJ, Braff D. Neural correlates of refixation saccades and antisaccades in normal and schizophrenia subjects. Biol Psychiatry. 2002 Feb 1; 51(3):216-23. PMID: 11839364.
        View in: PubMed
      102. Paulus MP, Hozack NE, Zauscher BE, Frank L, Brown GG, Braff D, Schuckit MA. Behavioral and functional neuroimaging evidence for prefrontal dysfunction in methamphetamine-dependent subjects. Neuropsychopharmacology. 2002 Jan; 26(1):53-63. PMID: 11751032.
        View in: PubMed
      103. Braff D, Geyer MA, Swerdlow NR. Human studies of prepulse inhibition of startle: normal subjects, patient groups, and pharmacological studies. Psychopharmacology (Berl). 2001 Jul; 156(2-3):234-58. PMID: 11549226.
        View in: PubMed
      104. Braff D, Geyer MA, Light GA, Sprock J, Perry W, Cadenhead KS, Swerdlow NR. Impact of prepulse characteristics on the detection of sensorimotor gating deficits in schizophrenia. Schizophr Res. 2001 Apr 15; 49(1-2):171-8. PMID: 11343875.
        View in: PubMed
      105. Braff D, Swerdlow NR, Geyer MA. Symptom correlates of prepulse inhibition deficits in male schizophrenic patients. Am J Psychiatry. 1999 Apr; 156(4):596-602. PMID: 10200740.
        View in: PubMed
      David's Networks
      Concepts
      Derived automatically from this person's publications.
      _
      Co-Authors
      People in Profiles who have published with this person.
      _
      Similar People
      People who share similar concepts with this person.
      _
      Same Department
      Physical Neighbors
      People whose addresses are nearby this person.
      _